Rubix LS Successfully Isolated Protein Binding Receptors Previously in Ebola and Leishmaniasis, by Providing Real-Time Rapid Spectral Analysis of Key Proteins, is Actively Adapting Its Technology to Target Coronavirus
WASHINGTON – Feb. 2, 2020 – Rubix LS engineered and deployed rapid diagnostic and elemental detection tools while actively working on studies of Ebola and Leishmaniasis, in both India and West Africa, which successfully resulted in the ability to rapidly identify and target affected patient population, as well as predictive patient diagnosis to aid in therapeutic intervention.
According to Rubix LS CEO Reginald Swift, “Our technology is now currently being adapted specifically for 2019-nCoV by targeting amino acid isolates and mutative protein binding changes from bronchoalveolar fluid through the breath of individuals. Our technology transformation will be completed within the days to come as the first case of the coronavirus was just reported in Massachusetts.”
The World Health Organization (WHO) declared coronavirus (2019-nCoV) a global health emergency. The rapid scale in which China, U.S, U.K and now India have produced exposure symptoms to coronavirus, has according to reports, caused more than 362 deaths, with 17205 cases in China, and 11 US cases reported, including 1 in Massachusetts where Rubix LS is headquartered.
The CDC Newsroom telebriefing of January 30, 2020, states the incubation period for coronavirus could be up to 14 days. When asked if it is possible to detect this virus before somebody is symptomatic, Dr. Nancy Messonnier from CDC responded, “We don’t know yet, and we’re looking closely to see if we can. This is where the technology of Rubix LS can aid and assist.
“There are two distinct ways. One part is actively sampling the individuals around these cases and taking samples from to record and learn more about how the virus is transmitted. There also are serological tests developed in the United States and elsewhere that could potentially help us learn more about a population level how exposure is taking place.”
The CDC also confirmed in a separate release that the virus has spread between two people in the United States, representing the first instance of person-to-person spread in the country. According to the CDC, MERS, and SARS, the other two coronaviruses that have emerged to cause serious illness in people exposed.
“Rubix LS uses Artificial Intelligence/Machine Learning (AI/ML) within it’s platform to specifically isolate protein binding receptor modifying behaviors that are able to target the prediction and precursor of the disease evolution and potential patient diagnosis.
“Our team has been working around the clock to refine the models for addressing these new epidemiological targets, and to build high-level accuracy in the findings.” states Swift. “In addition to Artificial Intelligence, our platform utilizes several skin-based sensor technologies, that are configured with communication tools, and can detect and provide a rapid spectral analysis of key proteins in real-time. The resulting databank of biological profiles can then be cross referenced and indexed by major health agencies, and research institutions worldwide, to fight the problem.“
Rubix LS has optimized it’s AI/ML platform to rapidly characterizing the “spike protein” changes that identify key differences from what is observed through 2019-nCOV, SARS & MERS, within minutes of running it’s model.
Leveraging the power and datastore of their platform, Rubix LS will compliment and augment epidemiological datasets gathered by other companies and organizations, to accurately target key configurations of mutation properties that represent a critical understanding in developing a vaccine.
“Rubix LS is presently in contact with the CDC to immediately initiate a development program to deploy a pilot study, and aggregate known and collected data, to disseminate to the greater scientific community and WHO authorities. and deploy robust countermeasure activities worldwide,” concludes Swift.
For questions regarding Rubix LS, contact the company at 855-639-5863, email@example.com
For any questions regarding updates to 2019-nCOV please visit the cdc.gov website.
Daisy Gallagher, Chief Public Information Officer